No safety or efficacy concerns have been flagged in recent updates, and the trial builds on five prior PBH studies demonstrating consistent benefits.For the most current details, check ClinicalTrials.gov (NCT06747468) or Amylyx's investor relations page.
So stock should pop when they announce full enrollment ...PPS action may be pre running that
Market Data 
Markets 
